Effects of COVID-19 on Dutch diabetes care

Autor: Jessica C.G. jessicabak, Erik H. Serné, Rolf H.H. Groenwold, Harold W. Valk, Mark H.H. Kramer, Max Nieuwdorp, Carianne L. Verheugt

Aims The COVID-19 pandemic impacted diabetes care by reducing diabetes outpatient visits and diabetes-related screening due to healthcare allocation. Yet the impact of COVID-19 on diabetes outpatients has not been extensively evaluated. This study ai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c364e3bee779a1dc333b1124c6bf1521
https://doi.org/10.21203/rs.3.rs-2876238/v1

The Value of Artificial Intelligence in Laboratory Medicine

Autor: Mark H.H. Kramer, Prabath W. B. Nanayakkara, Michiel Schinkel, R S Nannan Panday, Paul W. G. Elbers, Bo Schouten, Richard D. Hammer, Ketan Paranjape

Publikováno v: Paranjape, K, Schinkel, M, Hammer, R D, Schouten, B, Nannan Panday, R S, Elbers, P W G, Kramer, M H H & Nanayakkara, P 2021, ' The Value of Artificial Intelligence in Laboratory Medicine ', American Journal of Clinical Pathology, vol. 155, no. 6, pp. 823-831 . https://doi.org/10.1093/ajcp/aqaa170, https://doi.org/10.1093/ajcp/aqaa170
American Journal of Clinical Pathology, 155(6), 823-831. American Society of Clinical Pathologists
American Journal of Clinical Pathology
American journal of clinical pathology, 155(6), 823-831. American Society of Clinical Pathologists

Objectives As laboratory medicine continues to undergo digitalization and automation, clinical laboratorians will likely be confronted with the challenges associated with artificial intelligence (AI). Understanding what AI is good for, how to evaluat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e564c50deeb886bd8d0b1c6d7abae61f
http://www.scopus.com/inward/record.url?scp=85106667519&partnerID=8YFLogxK

Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes

Autor: Lennart Tonneijck, D. Margriet Ouwens, Mark M. Smits, Jordan Kraaijenhof, Mark H.H. Kramer, Marcel H.A. Muskiet, Daniël H. van Raalte

Publikováno v: Kraaijenhof, J, Muskiet, M H A, Tonneijck, L, Ouwens, D M, Kramer, M H H, van Raalte, D H & Smits, M M 2020, ' Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes : A secondary analysis of an 8-week, randomized, controlled, double-blind trial ', Diabetes, Obesity and Metabolism, vol. 22, no. 10, pp. 1847-1856 . https://doi.org/10.1111/dom.14107
Diabetes, Obesity and Metabolism, 22(10), 1847-1856. Wiley-Blackwell
Diabetes, Obesity & Metabolism

Aim To determine the glucose‐independent effect of the dipeptidyl peptidase‐4 (DPP‐4) inhibitor linagliptin versus the sulphonylurea glimepiride on systemic haemodynamics in the fasting and postprandial state in patients with type 2 diabetes (T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aadaca70671e98a7f6232eaeaae5f62
http://www.scopus.com/inward/record.url?scp=85087213101&partnerID=8YFLogxK

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes

Autor: Mark H.H. Kramer, Adrian Post, Ele Ferrannini, Marcel H.A. Muskiet, Erik J.M. van Bommel, Daniël H. van Raalte, Daan J Touw, Stephan J. L. Bakker, Max Nieuwdorp, Jaap A. Joles, Frank Geurts, Miranda van Berkel, Ewout J. Hoorn, A.H. Jan Danser

Publikováno v: Clinical science (London, England, 134(23), 3107-3118. Portland Press Ltd.
Clinical Science, 134(23), 3107-3118. Portland Press, Ltd.
Clinical Science, 134, 23, pp. 3107-3118
Clinical science (London, England : 1979), 134(23), 3107-3118
Clinical Science, 134, 3107-3118
van Bommel, E J M, Geurts, F, Muskiet, M H A, Post, A, Bakker, S J L, Danser, A H J, Touw, D J, van Berkel, M, Kramer, M H H, Nieuwdorp, M, Ferrannini, E, Joles, J A, Hoorn, E J & van Raalte, D H 2020, ' SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes ', Clinical science (London, England : 1979), vol. 134, no. 23, pp. 3107-3118 . https://doi.org/10.1042/CS20201274
Clinical Science, 134(23), 3107-3118. PORTLAND PRESS LTD

Sodium–glucose transporter (SGLT)2 inhibitors increase plasma magnesium and plasma phosphate and may cause ketoacidosis, but the contribution of improved glycemic control to these observations as well as effects on other electrolytes and acid–bas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3e88f7b816c8cec80fdf1b78fab60ac
https://doi.org/10.1042/cs20201274

DPARD

Autor: Max Nieuwdorp, Dick Mul, Harold W. de Valk, Mark H.H. Kramer, E.H. Serné, Petronella H. L. M. Geelhoed-Duijvestijn, Jessica C. G. Bak, Theo C J Sas, Carianne L. Verheugt

Publikováno v: BMC Endocrine Disorders, 21(1):122. BioMed Central
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-10 (2021)
BMC endocrine disorders, 21(1):122. BioMed Central
Bak, J C G, Mul, D, Serné, E H, de Valk, H W, Sas, T C J, Geelhoed-Duijvestijn, P H, Kramer, M H H, Nieuwdorp, M & Verheugt, C L 2021, ' DPARD : rationale, design and initial results from the Dutch national diabetes registry ', BMC Endocrine Disorders, vol. 21, no. 1, 122 . https://doi.org/10.1186/s12902-021-00782-x
BMC Endocrine Disorders, 21(1):122. BioMed Central Ltd.
BMC Endocrine Disorders

Background Treatment of diabetes mellitus has majorly improved over the past century, however, the disease burden is high and its prevalence still expanding. Further insight in the diabetes population is imperative to improve the quality of diabetes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb5aa99bd2a6efcf7c0f7502d6eff569
https://doi.org/10.1186/s12902-021-00782-x